• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小剂量卡维地洛对原发性高血压患者血压昼夜变化的影响。

The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.

作者信息

Ogihara T, Ikeda M, Goto Y, Yoshinaga K, Kumahara Y, Iimura O, Ishii M, Murakami E, Takeda T, Kokubu T

机构信息

Department of Medicine and Geriatrics, Osaka University Medical School, Japan.

出版信息

J Cardiovasc Pharmacol. 1987;10 Suppl 11:S108-12.

PMID:2454355
Abstract

The effect of once daily low-dose carvedilol on circadian variations of blood pressure (BP) was studied in Japanese patients with mild or moderate essential hypertension. Thirty-one patients were admitted to hospital whose BP was 150/90 mm Hg/day or greater and they participated in the study. After a placebo period of 1 week, 5 or 10 mg carvedilol was given once daily in the morning for 3 to 7 days, and if BP reduction was not sufficient, the dose was increased to 20 mg daily. The blood pressure variation was monitored before and 1, 2, 4, 6, 8, 10, 12, and 24 h after administration of the drug on the last day of placebo and final dose of carvedilol. Of the 31 cases receiving carvedilol once daily, cumulative effectiveness (13 mm Hg reduction in mean BP) was 48.4% at 10 mg/day and 54.8% at 20 mg/day. Both systolic and diastolic pressures decreased significantly and heart rate decreased slightly. There was no significant difference between the standard deviations of BP on the last days of the control period and the carvedilol treatment. The difference between maximum and minimum BP during the day was not significant between the two periods. Circadian variations of heart rate were also not significantly different for the two periods. This indicates that carvedilol did not have any effect on circadian variations of BP and heart rate. The present study also suggests that low-dose carvedilol once daily may be effective in the treatment of hypertension.

摘要

在日本轻度或中度原发性高血压患者中,研究了每日一次低剂量卡维地洛对血压(BP)昼夜变化的影响。31例收缩压≥150/90 mmHg的患者入院并参与本研究。经过1周的安慰剂期后,每天早晨给予5或10 mg卡维地洛,持续3至7天,如果血压降低不充分,则将剂量增加至每日20 mg。在安慰剂期最后一天和卡维地洛最后一剂给药前及给药后1、2、4、6、8、10、12和24小时监测血压变化。在31例每日服用一次卡维地洛的患者中,每日10 mg时累积有效率(平均血压降低13 mmHg)为48.4%,每日20 mg时为54.8%。收缩压和舒张压均显著降低,心率略有下降。对照期最后一天和卡维地洛治疗期最后一天的血压标准差之间无显著差异。两个时期白天最高血压与最低血压之间的差异不显著。两个时期心率的昼夜变化也无显著差异。这表明卡维地洛对血压和心率的昼夜变化没有任何影响。本研究还表明,每日一次低剂量卡维地洛可能对高血压治疗有效。

相似文献

1
The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.小剂量卡维地洛对原发性高血压患者血压昼夜变化的影响。
J Cardiovasc Pharmacol. 1987;10 Suppl 11:S108-12.
2
Controlled-release carvedilol in the treatment of essential hypertension.控释卡维地洛治疗原发性高血压
Am J Cardiol. 2006 Oct 2;98(7A):32L-38L. doi: 10.1016/j.amjcard.2006.07.017. Epub 2006 Aug 28.
3
Clinical efficacy of carvedilol in severe hypertension.卡维地洛治疗重度高血压的临床疗效。
J Cardiovasc Pharmacol. 1991;18 Suppl 4:S69-72.
4
Circadian antihypertensive profile of carvedilol (BM 14190).卡维地洛(BM 14190)的昼夜降压曲线
J Cardiovasc Pharmacol. 1987;10 Suppl 11:S119-23.
5
Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.每日一次卡维地洛与每日两次拉贝洛尔治疗轻至中度高血压的安全性和疗效比较。
Eur J Clin Pharmacol. 1990;38 Suppl 2:S164-6. doi: 10.1007/BF01409489.
6
Dose-effect relationship of carvedilol in essential hypertension. An open study.
Drugs. 1988;36 Suppl 6:75-81. doi: 10.2165/00003495-198800366-00014.
7
Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.卡维地洛治疗高血压:对血流动力学及24小时血压的影响
J Cardiovasc Pharmacol. 1992;19 Suppl 1:S27-34.
8
Effect of long-term carvedilol therapy on renal function in essential hypertension.长期卡维地洛治疗对原发性高血压患者肾功能的影响。
J Cardiovasc Pharmacol. 1992;19 Suppl 1:S97-101. doi: 10.1097/00005344-199219001-00019.
9
Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.与卡维地洛相比,替米沙坦对左心室质量影响的三维超声心动图和磁共振评估:一项多中心、随机、纵向研究
Am J Hypertens. 2005 Dec;18(12 Pt 1):1563-9. doi: 10.1016/j.amjhyper.2005.06.011.
10
Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.高血压患者中,控释卡维地洛与速释卡维地洛在稳态时的药代动力学和药效学比较。
Am J Cardiol. 2006 Oct 2;98(7A):17L-26L. doi: 10.1016/j.amjcard.2006.07.015. Epub 2006 Aug 28.

引用本文的文献

1
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.卡维地洛。对其药理特性及在心血管疾病治疗中的应用的重新评估。
Drugs. 1997 Jul;54(1):161-85. doi: 10.2165/00003495-199754010-00015.
2
Clinical pharmacokinetics and pharmacodynamics of carvedilol.卡维地洛的临床药代动力学与药效学
Clin Pharmacokinet. 1994 May;26(5):335-46. doi: 10.2165/00003088-199426050-00002.
3
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.卡维地洛。对其药效学、药代动力学特性及治疗效果的综述。
Drugs. 1993 Feb;45(2):232-58. doi: 10.2165/00003495-199345020-00006.
4
Drug treatment of hypertension.高血压的药物治疗
Drugs. 1988;35 Suppl 6:40-52. doi: 10.2165/00003495-198800356-00006.
5
Dose-effect relationship of carvedilol in essential hypertension. An open study.
Drugs. 1988;36 Suppl 6:75-81. doi: 10.2165/00003495-198800366-00014.
6
Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.卡维地洛对脊髓麻醉自发性高血压大鼠血管舒张作用的机制分析。
Drugs. 1988;36 Suppl 6:31-6. doi: 10.2165/00003495-198800366-00007.
7
Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.卡维地洛治疗肾性高血压的疗效与安全性:一项开放性短期研究。日本卡维地洛肾性高血压研究组
Drugs. 1988;36 Suppl 6:129-35. doi: 10.2165/00003495-198800366-00022.
8
The use of carvedilol in elderly hypertensive patients.
Eur J Clin Pharmacol. 1990;38 Suppl 2:S129-33. doi: 10.1007/BF01409482.